Anthera Pharmaceuticals, Inc. (ANTH)

OTCMKTS: ANTH · Delayed Price · USD
0.00 (0.00%)
Sep 27, 2022 10:04 AM EDT - Market open
Market Cap 617,832
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 6.18B
EPS (ttm) -1.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6
Open 0.0001
Previous Close 0.0001
Day's Range 0.0001 - 0.0001
52-Week Range 0.0000 - 0.0008
Beta -125.17
Analysts Buy
Price Target n/a
Earnings Date n/a

About ANTH

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license ... [Read more...]

Industry Biotechnology
IPO Date Mar 1, 2010
CEO J. Craig Thompson
Employees 21
Stock Exchange OTCMKTS
Ticker Symbol ANTH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target
Analyst Consensus: Buy
Stock Forecasts


AM Best Assigns Issue Credit Ratings to Anthem, Inc.'s New Senior Unsecured Notes

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has assigned Long Term Issue Credit Ratings of “bbb+” to the newly issued senior unsecured notes of Anthem, Inc. (Anthem) (Indianapolis, IN) [NYSE:ANTH], which to...

1 year ago - Business Wire

AM Best Comments on Credit Ratings of Anthem, Inc. and Its Subsidiaries Following MMM Holdings, LLC Acquisition Annou...

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has commented that the Credit Ratings (ratings) of Anthem, Inc. (Anthem) (Indianapolis, IN) [NYSE: ANTH] and its insurance subsidiaries remain unchanged following...

1 year ago - Business Wire